– UK, Chippenham – Vectura Group plc (LON: VEC) today announced the appointment of Jeanne Thoma as the Senior Independent Director, succeeding Dr. Thomas Werner who stepped down as a Non-Executive Director and the Senior Independent Director with effect from the AGM.
“We are delighted that Jeanne Thoma will be taking up the role as the new Senior Independent Director,” said Board Chairman, Bruno Angelici.
He added: “Thomas’ contribution, initially to Skyepharma and later to Vectura, has been remarkable. His deep experience and business judgment will be missed.”
About Vectura
Vectura is a leading specialist inhalation CDMO that provides innovative inhaled drug delivery solutions that enable customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has twelve key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For more information: https://www.vectura.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
